Integrated Filing — IndAS

General information about company
Scrip Code	544067
NSE Symbol	INNOVACAP
MSEI Symbol	NOTLISTED
ISIN	INE0DUT01020
Name of company	INNOVA CAPTAB LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	19-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	12-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Drugs and Pharmaceutical products
Start date and time of board meeting	19-May-2025   15:38:00
End date and time of board meeting	19-May-2025   17:35:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2025-02-05
Indicate Company website link for updated RPT policy of the Company	https://www.innovacaptab.com/corporate-governance.php
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes
No. of times funds raised during the quarter	1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	Yes

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	2425220000	9580610000
	Other income	43560000	167750000
	Total income	2468780000	9748360000
2	Expenses
(a)	Cost of materials consumed	1874180000	7155100000
(b)	Purchases of stock-in-trade	2340000	6840000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-136070000	-113420000
(d)	Employee benefit expense	213210000	627430000
(e)	Finance costs	18690000	21680000
(f)	Depreciation, depletion and amortisation expense	78120000	170150000
(f)	Other Expenses
1	Power and fuel	54210000	150690000
2	Packing charges	28200000	94940000
3	Stores and spares consumed	21120000	72440000
4	Repairs and maintenance	15480000	54680000
5	Miscellaneous expenses	17780000	151610000
6	Lab consumables	7830000	37090000
7	Bad debts written off	14400000	32850000
8	Rates, fees and taxes	9350000	31410000
9	House keeping expense	11550000	30010000
10	Travelling and conveyance	9840000	25950000
	Total other expenses	189760000	681670000
	Total expenses	2240230000	8549450000
3	Total profit before exceptional items and tax	228550000	1198910000
4	Exceptional items	0	0
5	Total profit before tax	228550000	1198910000
6	Tax expense
7	Current tax	27410000	220000000
8	Deferred tax	29890000	84210000
9	Total tax expenses	57300000	304210000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	171250000	894700000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	171250000	894700000
17	Other comprehensive income net of taxes	580000	-2220000
18	Total Comprehensive Income for the period	171830000	892480000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	572250000	572250000
	Face value of equity share capital	10	10
27	Details of debt securities
22	Reserves excluding revaluation reserve		7557400000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	2.99	15.63
	Diluted earnings (loss) per share from continuing operations	2.99	15.63
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	2.99	15.63
	Diluted earnings (loss) per share from continuing and discontinued operations	2.99	15.63
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results		The above standalone financial results of Innova Captab Limited the Company have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards Ind AS notified under Section 133 of the Companies Act 2013 the act read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations, 2015 Listing Regulation as amended. The results for the quarter and year ended 31 March 2025 are available on the Companys website i.e. www.innovacaptab.com under investor information section and on the stock exchange website i.e. www.bseindia.com and www.nseindia.com. n nThe above standalone financial results have been reviewed and recommended by Audit Committee at its meeting held on 19 May 2025. The Board of Directors at their meeting held on 19 May 2025 have approved the above results and taken them on record. The statutory auditors of the Company have expressed an unmodified opinion on the audited standalone financial results for the quarter and year ended 31 March 2025. n nThe Company has only one reportable segment i.e. Drugs and pharmaceutical products as per Ind-AS 108 Operating Segments specified under section 133 of the Companies Act, 2013. Accordingly the disclosures as per the listing agreement are not applicable to the group. n nThe figures of the last quarter of the year ended 31 March 2025 and the corresponding quarter ended in the previous year as reported in these annual financial results are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the financial year. Also the figures upto the end of the third quarter had only been reviewed and not subject to audit.

Remarks
Debt equity ratio
Debt service coverage ratio	Earning available for Debt Service is 1084.53 mn. however, total interest and principal repayments are 440.79 mn.
Interest service coverage ratio	EBIDTA is 8.5 times of Interest paid and such increase in EBIDTA is due to generl increase in operations.

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	6369110000
	Capital work-in-progress	210150000
	Investment property	0
	Goodwill	0
	Other intangible assets	5570000
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	600000000
	Trade receivables, non-current	0
	Loans, non-current	1077680000
	Other non-current financial assets	65530000
	Total non-current financial assets	1743210000
	Deferred tax assets (net)	0
	Other non-current assets	32320000
	Total non-current assets	8360360000
2	Current assets
	Inventories	1399450000
	Current financial asset
	Current investments	0
	Trade receivables, current	2489010000
	Cash and cash equivalents	153070000
	Bank balance other than cash and cash equivalents	525850000
	Loans, current	5720000
	Other current financial assets	314440000
	Total current financial assets	3488090000
	Current tax assets (net)	0
	Other current assets	403540000
	Total current assets	5291080000
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	13651440000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	572250000
	Other equity	7557400000
	Total equity attributable to owners of parent	8129650000
	Non controlling interest
	Total equity	8129650000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	2448940000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	0
	Total non-current financial liabilities	2448940000
	Provisions, non-current	39340000
	Deferred tax liabilities (net)	131870000
	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	Total non-current liabilities	2620150000
	Current liabilities
	Current financial liabilities
	Borrowings, current	842830000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	88320000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1673200000
	Total Trade payable	1761520000
	Other current financial liabilities	225960000
	Total current financial liabilities	2830310000
	Other current liabilities	26730000
	Provisions, current	9250000
	Current tax liabilities (Net)	35350000
	Deferred government grants, Current	0
	Total current liabilities	2901640000
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	5521790000
	Total equity and liabilites	13651440000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments	Textual Information(2)

Text Block
Textual Information(2)	The Companys operations relate to only one reportable segment viz Drugs and Pharmaceuticals. Accordingly no separate disclosure of segment information is required.

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Remeasurement of defined benefit obligation	780000	-2980000
	Total Amount of items that will not be reclassified to profit and loss	780000	-2980000
2	Income tax relating to items that will not be reclassified to profit or loss	200000	-760000
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss
5	Total Other comprehensive income	580000	-2220000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			1198910000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			0
	Adjustments for decrease (increase) in inventories			-459050000
	Adjustments for decrease (increase) in trade receivables, current			-356170000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-73980000
	Adjustments for decrease (increase) in other non-current assets			440000
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			-299310000
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			226400000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			-8840000
	Adjustments for increase (decrease) in other non-current liabilities			-1350000
	Adjustments for depreciation and amortisation expense			170150000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			3850000
	Adjustments for provisions, current			12270000
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			19690000
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			4340000
	Adjustments for dividend income			0
	Adjustments for interest income			0
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			800000
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			71050000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-689710000
	Net cash flows from (used in) operations			509200000
	Dividends received			0
	Interest paid			-21680000
	Interest received			-138920000
	Income taxes paid (refund)			193950000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			198010000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			1480000
	Purchase of property, plant and equipment			1609290000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			295000000
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			147790000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			167560000
	Net cash flows from (used in) investing activities	-997460000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			976150000
	Repayments of borrowings			114030000
	Payments of lease liabilities			7550000
	Dividends paid			0
	Interest paid			15940000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			838630000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			39180000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			0
	Net increase (decrease) in cash and cash equivalents			39180000
	Cash and cash equivalents cash flow statement at beginning of period			113890000
	Cash and cash equivalents cash flow statement at end of period			153070000

Signatory Details
Name of signatory	Neeharika Shukla
Designation of person	Company Secretary and Compliance Officer
Place	Chandigarh
Date	19-May-2025